CG
KPTI icon

Cutler Group’s Karyopharm Therapeutics KPTI Stock Holding History

Cutler Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-680
Closed -$2K – 4847
2022
Q3 		$2K Sell
680
-587
-46% -$43.8K ﹤0.01% 4233
2022
Q2 		$3K Sell
1,267
-3,160
-71% -$290K ﹤0.01% 4062
2022
Q1 		$44K Buy
+4,427
New +$552K ﹤0.01% 2362
2017
Q4 		– Sell
-700
Closed -$19K – 5424
2017
Q3 		$19K Sell
700
-373
-35% -$53.4K ﹤0.01% 3180
2017
Q2 		$13K Buy
1,073
+166
+18% +$24.6K ﹤0.01% 3888
2017
Q1 		$21K Buy
907
+614
+210% +$98.6K ﹤0.01% 3275
2016
Q4 		$2K Sell
293
-480
-62% -$64.9K ﹤0.01% 5629
2016
Q3 		$16K Buy
773
+240
+45% +$28.8K ﹤0.01% 3654
2016
Q2 		$5K Buy
533
+60
+13% +$7.79K ﹤0.01% 4937
2016
Q1 		$2K Sell
473
-1,307
-73% -$144K ﹤0.01% 5592
2015
Q4 		$19K Buy
+1,780
New +$385K ﹤0.01% 3462

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cutler Group's KPTI Position: Q1 2023 in Review

Cutler Group sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 321 shares — an estimated $16K sold.

Cutler Group first reported a position in KPTI in Q4 2015 and held it in 13 quarters. The position peaked at $113K in Q1 2017. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • Cutler Group reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 321 Karyopharm Therapeutics shares in Q1 2023, an estimated $16K.
  • Cutler Group first reported a position in Karyopharm Therapeutics in Q4 2015 and held it in 13 quarters.
  • Cutler Group's Karyopharm Therapeutics position peaked at $113K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.